Molecular mechanisms of drug resistance and its reversal in cancer

Abstract

Chemotherapy is the main strategy for the treatment of cancer. However, the main problem limiting the success of chemotherapy is the development of multidrug resistance. The resistance can be intrinsic or acquired. The resistance phenotype is associated with the tumor cells that gain a cross-resistance to a large range of drugs that are structurally and functionally different. Multidrug resistance arises via many unrelated mechanisms, such as overexpression of energy-dependent efflux proteins, decrease in uptake of the agents, increase or alteration in drug targets, modification of cell cycle checkpoints, inactivation of the agents, compartmentalization of the agents, inhibition of apoptosis and aberrant bioactive sphingolipid metabolism. Exact elucidation of resistance mechanisms and molecular and biochemical approaches to overcome multidrug resistance have been a major goal in cancer research. This review comprises the mechanisms guiding multidrug resistance in cancer chemotherapy and also touches on approaches for reversing the resistance.

• ABC transporters
• apoptosis
• bioactive sphingolipids
• cancer
• cell cycle alteration
• multidrug resistance

Declaration of interest

None of the authors have any interests, which might influence the compilation of the current literature in this subject. We apologize to the authors whose valuable studies were not included here due to space limitations and the concentrated scope of the review.

Supplementary material available online

Supplementary Data 1–13